{"paper_id": "501ae7b9e307bf0050b9490f664c925a78ab9134", "metadata": {"title": "Supporting Material Computational Modeling of the Bat HKU4 Coronavirus 3CLpro Inhibitors as a Tool for the Development of Antivirals against the Emerging Middle East Respiratory Syndrome (MERS) Coronavirus", "authors": [{"first": "Areej", "middle": [], "last": "Abuhammad", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Jordan", "location": {"postCode": "11942", "settlement": "Amman", "country": "Jordan"}}, "email": "a.abuhammad@ju.edu.jo"}, {"first": "", "middle": [], "last": "Rua&apos;", "suffix": "", "affiliation": {}, "email": ""}, {"first": "A", "middle": [], "last": "Al-Aqtash", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Jordan", "location": {"postCode": "11942", "settlement": "Amman", "country": "Jordan"}}, "email": ""}, {"first": "Brandon", "middle": ["J"], "last": "Anson", "suffix": "", "affiliation": {"laboratory": "", "institution": "Purdue University", "location": {"settlement": "West Lafayette", "region": "Indiana", "country": "USA"}}, "email": ""}, {"first": "Andrew", "middle": ["D"], "last": "Mesecar", "suffix": "", "affiliation": {"laboratory": "", "institution": "Purdue University", "location": {"settlement": "West Lafayette", "region": "Indiana", "country": "USA"}}, "email": ""}, {"first": "Mutasem", "middle": ["O"], "last": "Taha", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Jordan", "location": {"postCode": "11942", "settlement": "Amman", "country": "Jordan"}}, "email": ""}]}, "abstract": [{"text": "Fourteen training subsets (Subsets A to N, Table S2 ) from the total collected list of compounds (Table S1 ) were used to explore the pharmacophoric space of the target enzyme.", "cite_spans": [], "ref_spans": [{"start": 43, "end": 51, "text": "Table S2", "ref_id": null}, {"start": 97, "end": 106, "text": "(Table S1", "ref_id": null}], "section": "Abstract"}, {"text": "The training subsets were selected in such a way that each subset resembles certain hypothetical binding mode. The member molecules in each training subset were carefully assessed to ensure that the differences in their inhibitory bioactivities are primarily attributable to the presence or absence of pharmacophoric features (e.g., HBA or HBD or Hbic or RingArom) rather than steric shielding and/or bioactivity enhancing or -reducing auxiliary groups (e.g., electron donating or withdrawing groups).", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "\uf0b7 S1 Conformational Analysis 3 \uf0b7 S2 Training Subsets Selection for Exploring of HKU4-CoV 3CL pro Pharmacophoric Space 4 \uf0b7 S3 Pharmacophore Modeling 5 \uf0b7 S4 Assessment of the Generated Hypotheses 7 \uf0b7 S5 Clustering of the Generated Pharmacophore Hypotheses 9 \uf0b7 S6 Genetic Function Approximation (GFA) Method 10 \uf0b7 S7 MLR-Based QSAR Modeling 11 \uf0b7 S8 Addition of Exclusion Volumes 12 \uf0b7 S9 LibDock Docking Engine and Settings 14 \uf0b7 S10 CDOCKER Docking Engine and Settings 15 \uf0b7 S11 Scoring of Docked Ligand Poses. 16 \uf0b7 S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA). 17 \uf0b7 S13 Genetic Algorithm Implementation in dbCICA Modeling 19 \uf0b7 S14 Building Pharmacophores Corresponding to Successful dbCICA Models. 20 \uf0b7 S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis 22 \uf0b7 Table S1 : The structures of HKU4-CoV 3CL pro inhibitors utilized in modeling. 25 \uf0b7 Table S2 : Training subsets (extracted from Table S1) employed in exploring the pharmacophoric space of HKU4-CoV 3CL pro inhibitors. 48 \uf0b7 Table S3 : Training subsets and HYPOGEN run parameters employed for exploring HKU4-CoV 3CL pro pharmacophoric space. 49 \uf0b7 Table S4 : The performance of the best representatives of clustered pharmacophore hypotheses generated for HKU4-CoV 3CL pro . 54 \uf0b7 Table S5 : Pharmacophoric features and corresponding weights, tolerances and 3D coordinates of Hypo(L-T5-2), Hypo(K-T5-3),and Hypo(N-T1-1) selected by QSAR-guided method. 57 \uf0b7 Table S6 : Training subset used for adding excluded spheres for Hypo(K-T5-3/N-T1-1) using HIPHOP-REFINE module of CATALYST. 58 \uf0b7 Table S7 : HKU4-CoV 3CL pro based pharmacophore models selected by best dbCICA models. 59 \uf0b7 Table S8 : Captured hits by dbCICA derived pharmacophores. 60 \uf0b7 Table S9 : Captured hits by QSAR-guided pharmacophores. 61 \uf0b7 Figure S1 : NMR and MS analysis of compound 222. 62 \uf0b7 Figure S2 : NMR and MS analysis of compound 223. 63 \uf0b7 Figure S3 : NMR and MS analysis of compound 224. \uf0b7 Figure S4 : The dose-response curves of compounds 222 and 223 against MERS-CoV 3CL pro 64", "cite_spans": [], "ref_spans": [{"start": 799, "end": 807, "text": "Table S1", "ref_id": "TABREF3"}, {"start": 883, "end": 891, "text": "Table S2", "ref_id": "TABREF6"}, {"start": 1021, "end": 1029, "text": "Table S3", "ref_id": "TABREF7"}, {"start": 1143, "end": 1151, "text": "Table S4", "ref_id": "TABREF11"}, {"start": 1274, "end": 1282, "text": "Table S5", "ref_id": null}, {"start": 1450, "end": 1458, "text": "Table S6", "ref_id": "TABREF14"}, {"start": 1579, "end": 1587, "text": "Table S7", "ref_id": "TABREF15"}, {"start": 1671, "end": 1679, "text": "Table S8", "ref_id": "TABREF16"}, {"start": 1735, "end": 1743, "text": "Table S9", "ref_id": "TABREF17"}, {"start": 1796, "end": 1805, "text": "Figure S1", "ref_id": null}, {"start": 1850, "end": 1859, "text": "Figure S2", "ref_id": null}, {"start": 1904, "end": 1913, "text": "Figure S3", "ref_id": null}, {"start": 1955, "end": 1964, "text": "Figure S4", "ref_id": null}], "section": "Contents:"}, {"text": "All chemical and biological data used in modeling are taken from reference [36] . The 2D", "cite_spans": [{"start": 75, "end": 79, "text": "[36]", "ref_id": null}], "ref_spans": [], "section": "S1 Conformational Analysis"}, {"text": "structures of the inhibitors were imported into CATALYST and converted automatically into plausible 3D single conformer representations. The resulting 3D structures were used as starting points for conformational analysis and in the determination of various molecular descriptors for QSAR modeling.", "cite_spans": [], "ref_spans": [], "section": "S1 Conformational Analysis"}, {"text": "The molecular flexibility of modeled compounds was taken into account by considering each compound as a collection of conformers within certain energy range. The \"Best Conformation", "cite_spans": [], "ref_spans": [], "section": "S1 Conformational Analysis"}, {"text": "Generation\" option implemented within Discovery Studio was used to explore the conformational space of each inhibitor (1-221, Table S1 ) based on the generalized CHARMm force field implemented in Discovery Studio. The conformational space of each inhibitor was extensively sampled utilizing the poling algorithm employed within the CONFIRM module of CATALYST and via the 'Best' module to ensure extensive sampling of conformational space.", "cite_spans": [], "ref_spans": [{"start": 126, "end": 134, "text": "Table S1", "ref_id": "TABREF3"}], "section": "S1 Conformational Analysis"}, {"text": "Efficient conformational coverage guarantees minimum conformation-related noise during pharmacophore generation and validation stages.", "cite_spans": [], "ref_spans": [], "section": "S1 Conformational Analysis"}, {"text": "Default parameters were implemented, i.e., a conformational ensemble was produced with an energy threshold \u2264 20 kcal/mol from the local minimized structure and a maximum limit of 255 conformers for each molecule.", "cite_spans": [], "ref_spans": [], "section": "S1 Conformational Analysis"}, {"text": "Pharmacophore modeling using Discovery Studio proceeds through three successive phases:", "cite_spans": [], "ref_spans": [], "section": "S3 Pharmacophore Modeling"}, {"text": "constructive, subtractive and optimization phases. During the constructive phase, Discovery", "cite_spans": [], "ref_spans": [], "section": "S3 Pharmacophore Modeling"}, {"text": "Studio uses the most-active training compounds to produce common conformational alignments among them. Only alignments based on a maximum of five chemical features are taken into consideration. Discovery Studio identifies a specified compound as being within the most active category according to Equation (S1).", "cite_spans": [], "ref_spans": [], "section": "S3 Pharmacophore Modeling"}, {"text": "(MAct x UncMAct) -(Act / UncAct) > 0.0 \u2026\u2026\u2026\u2026.. (S1)", "cite_spans": [], "ref_spans": [], "section": "S3 Pharmacophore Modeling"}, {"text": "Where \"MAct\" is the activity of the most active compound in the training subset under consideration, \"Act\" is the activity of the training compound under question, and \"Unc\" is the uncertainty of the compounds. However, if more than eight compounds satisfy Equation (S1), then only the top eight are considered as being most-active category. The remaining compounds are considered of intermediate potencies.", "cite_spans": [], "ref_spans": [], "section": "S3 Pharmacophore Modeling"}, {"text": "In the subsequent subtractive phase, Discovery Studio excludes hypotheses that fit inactive training compounds. A specified training compound is defined as being inactive if it satisfies Equation (S2).", "cite_spans": [], "ref_spans": [], "section": "S3 Pharmacophore Modeling"}, {"text": "Where \"BS\" is the bioactivity spread. This value was set to 2.4, 2.5, or 3.4 as shown in Table   S2 . These values were selected based on the bioactivity spreads of each corresponding training subset.", "cite_spans": [], "ref_spans": [{"start": 89, "end": 99, "text": "Table   S2", "ref_id": "TABREF6"}], "section": "Log (Act) -log (MAct) > BS \u2026\u2026\u2026\u2026. (S2)"}, {"text": "The last step in the pharmacophore generation process is the optimization phase in which Discovery Studio implements fine perturbations to high-ranking binding hypotheses that survived the subtractive phase. These modifications are done in the form of vectored feature rotation, adding new feature and/or subtracting another feature, in order to find new models of enhanced bioactivity-fit correlation. At the end of each automatic modeling run, the program chooses the highest-ranking models (10 by default) and presents them as the optimal pharmacophore hypotheses.", "cite_spans": [], "ref_spans": [], "section": "Log (Act) -log (MAct) > BS \u2026\u2026\u2026\u2026. (S2)"}, {"text": "The pharmacophoric space of each training subset was explored through eight automatic pharmacophore modeling runs (as in Table S3 ) using the CATALYST module of the Discovery Studio. Pharmacophore exploration trials involved varying the interfeature spacing parameter (100 and 300 picometers), the maximum number of pharmacophoric features from 4 to 5 or 5 to 5, and the addition of either 0 or up to 10 exclusion spheres (Table S3) .", "cite_spans": [], "ref_spans": [{"start": 121, "end": 129, "text": "Table S3", "ref_id": "TABREF7"}, {"start": 422, "end": 432, "text": "(Table S3)", "ref_id": "TABREF7"}], "section": "Log (Act) -log (MAct) > BS \u2026\u2026\u2026\u2026. (S2)"}, {"text": "During the generation of hypotheses, Discovery Studio minimizes certain cost function consisting of three terms: weight cost, error cost, and configuration cost.", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "Weight cost is a value that increases when the feature weight in a model deviates from an ideal Where, mapped hypothesis features represents the number of pharmacophore features that successfully superimpose (i.e., overlap or map with) corresponding chemical moieties within the fitted compound. W is the weight of the corresponding hypothesis feature spheres. This value is fixed to 1.0 in Discovery Studio-generated models. disp is the distance between the center of a particular pharmacophoric sphere (feature centroid), and the center of the corresponding overlapped chemical moiety of the fitted compound. Tol, or Tolerance, is the radius of the pharmacophoric feature sphere. \u03a3(disp/tol) 2 is the summation of (disp/tol) 2 values for all pharmacophoric features that successfully map corresponding chemical functionalities in the fitted compound.", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "The third cost term, which is known as \"configuration cost\" (Config cost), penalizes the complexity of the hypothesis. This is a fixed cost, which is equal to the entropy of the hypothesis space. The more features (a maximum of five) in a generated hypothesis, the higher the entropy with consequent increase in this cost.", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "The overall cost (total cost) of a hypothesis is obtained by summing over the three cost factors.", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "However, error cost is the main contributor to total cost. Furthermore, Discovery Studio-HYPOGEN calculates the cost of the null hypothesis, which assumes that there is no relationship in the data and that experimental activities are normally distributed about their mean. Accordingly, the greater the difference from the null hypothesis cost, the more likely that the hypothesis does not reflect chance correlation. In a successful automatic modeling run, Discovery Studio-HYPOGEN ranks the generated models according to their total costs.", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "Another approach to assess the quality of Discovery Studio-HYPOGEN pharmacophores is to cross-validate them using the Cat-Scramble program. This validation process is based on", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "Fischer's randomization test.", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "In this validation test, we chose a 90% confidence level, which instruct Discovery Studio-HYPOGEN to generate 9 random spreadsheets by the Cat-Scramble command. Subsequently, Discovery Studio-HYPOGEN is challenged to employ these random spreadsheets to generate hypotheses using exactly the same features and parameters used in generating the initial unscrambled hypotheses. Success in generating pharmacophores of comparable cost criteria to those produced by the original unscrambled data reduces the confidence in the unscrambled original pharmacophore models and the training compounds. Based on Fischer randomization criteria, 677 pharmacophores exceeded the 80% significance threshold for subsequent processing (i.e., clustering and QSAR analyses).", "cite_spans": [], "ref_spans": [], "section": "S4 Assessment of the Generated Hypotheses"}, {"text": "The successful models (677) were clustered into 68 groups utilizing the hierarchical average linkage method available in CATALYST. Subsequently, the highest ranking representatives, as judged based on their significance F-value, were selected to represent their corresponding clusters in subsequent QSAR modeling. Table S4 shows information about representative pharmacophores including their pharmacophoric features, success criteria and differences from corresponding null hypotheses. The table also shows the corresponding Cat-Scramble confidence levels for each representative pharmacophore.", "cite_spans": [], "ref_spans": [{"start": 314, "end": 322, "text": "Table S4", "ref_id": "TABREF11"}], "section": "S5 Clustering of the Generated Pharmacophore Hypotheses"}, {"text": "GFA operates through a cycle composed of: (i) encoding mechanism; (ii) definition of a fitness function; (iii) creating a population of chromosomes; (iv) genetic manipulation of chromosomes. We implemented a gene-based encoding system. In this scheme, the possible models (chromosomes) differ from one another by the set of independent descriptors variables (genes). If the general number of genes is equal to P (in this particular case, P = 331 variable corresponding to 68 pharmacophore fit values and 263 calculated descriptors), the chromosome corresponding to any model consists of a string of P binary digits (bits) or genes.", "cite_spans": [], "ref_spans": [], "section": "S6 Genetic Function Approximation (GFA) Method"}, {"text": "Each value in the string represents an independent variable (0 = absent, 1 = present). Each chromosome is associated with a fitness value that reflects how good it is compared to other solutions. The followings are parameters used in the GFA-based selection of descriptors:", "cite_spans": [], "ref_spans": [], "section": "S6 Genetic Function Approximation (GFA) Method"}, {"text": "\uf0b7 Creating an initial population: number of starting random chromosomes. GFA parameters were employed: explore linear, quadratic and spline equations at mating and mutation probabilities of 50%; population size = 500; number of genetic iterations (generations) = 10,000 and LOF smoothness parameter = 0.5. However, to determine the optimal number of explanatory terms (QSAR descriptors), it was decided to scan and evaluate all possible QSAR models resulting from 4 to 7 explanatory terms. All QSAR models were validated employing leave one-out r 2 (r 2 LOO ) and predictive r 2 (r 2 PRESS ) calculated from the randomly selected external test subset (see Table S1 under Supporting Material). The predictive r 2 PRESS is defined as in Equation S5.", "cite_spans": [], "ref_spans": [{"start": 656, "end": 664, "text": "Table S1", "ref_id": "TABREF3"}], "section": "S6 Genetic Function Approximation (GFA) Method"}, {"text": "Where \"SD\" is the sum of the squared deviations between the biological activities of the test set and the mean activity of the training set molecules, \"PRESS\" is the squared deviations between predicted and actual activity values for every molecule in the test set.", "cite_spans": [], "ref_spans": [], "section": "S6 Genetic Function Approximation (GFA) Method"}, {"text": "A subset of 177 compounds from the total list of inhibitors (1-221, Table S1 ) was selected to be used as a training set for QSAR modeling. The remaining 44 molecules were utilized as an external test subset for validating QSAR models. The test molecules were selected as follows:", "cite_spans": [], "ref_spans": [{"start": 68, "end": 76, "text": "Table S1", "ref_id": "TABREF3"}], "section": "S6 Genetic Function Approximation (GFA) Method"}, {"text": "The 221 inhibitors were ranked according to their IC 50 values, and then every fifth compound was selected for the testing set starting from the high-potency end. A subset of training compounds were carefully selected for HIPHOP-REFINE modelling of pharmacophores Hypo(K-T5-3/N-T1-1) as in Table S6 . It was decided to consider the IC 50 value of 10 \u00b5M as an arbitrary activity\u2044inactivity threshold and so compounds with values more than 10 \u00b5M considered as \"inactives\" with principal zero, and were carefully evaluated to assess whether their lower potencies are attributable to missing one or more pharmacophoric features, i.e. compared to active compounds (MaxOmitFeat = 1 or 2), or related to possible steric clashes within the binding pocket (MaxOmitFeat = 0). HIPHOP-REFINE was configured to permit a maximum of 100 exclusion spheres to be added to the pharmacophoric hypotheses.", "cite_spans": [], "ref_spans": [{"start": 290, "end": 298, "text": "Table S6", "ref_id": "TABREF14"}], "section": "S6 Genetic Function Approximation (GFA) Method"}, {"text": "LibDock enables rapid screening of combinatorial libraries where conformations of the ligands are aligned to polar and apolar receptor interactions sites (i.e., hotspots).", "cite_spans": [], "ref_spans": [], "section": "S9 LibDock Docking Engine and Settings"}, {"text": "Conformations can be either pre-calculated or generated on the fly. Since some of the output poses may have hydrogen atoms in close proximity to the receptor, a CHARMm minimization step can be optionally enabled to further optimize the docked poses.", "cite_spans": [], "ref_spans": [], "section": "S9 LibDock Docking Engine and Settings"}, {"text": "LibDock docking follows the following steps: (i) Remove hydrogen atoms, (ii) Rank ligand conformations and prune by solvent accessible surface area (SASA), (iii) find hotspots using a grid that is placed into the binding site and using polar and apolar probes. The numbers of hotspots are pruned by clustering to a user defined value, (iv) Dock ligand poses by aligning to binding site hotspots. This is performed by using triplets (i.e., three ligand atoms are aligned to three receptor hotspots). ", "cite_spans": [], "ref_spans": [], "section": "S9 LibDock Docking Engine and Settings"}, {"text": "CDOCKER is a CHARMm-based simulated annealing/molecular dynamics method that uses rigid receptor for docking. CDOCKER protocol includes the following steps. To enhance performance and shorten calculation times, nonbond energy grid is used for interaction energy calculations, rather than the full potential energy terms usually used by CHARMm.", "cite_spans": [], "ref_spans": [], "section": "S10 CDOCKER Docking Engine and Settings"}, {"text": "The following CDOCKER parameters were implemented in the presented project: (i) A binding site sphere of 9.7 \u00c5 radius surrounding the centre of the co-crystallized ligand. (ii)", "cite_spans": [], "ref_spans": [], "section": "S10 CDOCKER Docking Engine and Settings"}, {"text": "Initially, starting ligands' conformers were energy-minimized then heated to 1000 K over 1000 molecular dynamics steps (these include heating and equilibration phases) to generate 10 starting random conformations for each ligand. (iii) Each random conformer was rotated 10 times within the binding pocket for subsequent energy refinement. The van der Waals energies of the resulting conformers/poses were evaluated and those of \u2265 300 kcal/mol were discarded (not exceeding 800 bad conformers/poses). (iv) Remaining conformers/poses were exposed to a cycle of simulated annealing over 2000 heating steps to targeted temperature of 700 K followed by 5000 cooling steps to targeted temperature of 300 K. (v) The docked poses were energy minimized to a final minimization gradient tolerance zero Kcal/mol/\u00c5. (vi) Top 10 poses were saved for subsequent scoring. CDOCKER failed to dock compound 25 (Table S1) into the anhydrous version of the protein and was therefore excluded from subsequent CDOCKER-based dbCICA modeling.", "cite_spans": [], "ref_spans": [{"start": 892, "end": 902, "text": "(Table S1)", "ref_id": "TABREF3"}], "section": "S10 CDOCKER Docking Engine and Settings"}, {"text": "LigScore1 and LigScore2 scores were calculated employing CFF force field (version 1.02) and using grid-based energies with a grid extension of 7.5 \u00c5 across the binding site. PMF scores were calculated employing cutoff distances of 12.0 \u00c5 for carbon-carbon interactions and other atomic interactions, while PMF04 scores were calculated employing cutoff values of 6.0 and 9.0 \u00c5 for carbon-carbon interactions and other atomic interactions, respectively.", "cite_spans": [], "ref_spans": [], "section": "S11 Scoring of Docked Ligand Poses."}, {"text": "dbCICA consists of the following sequential steps:", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "(i) The docked poses/conformers of each ligand (based on a particular docking condition, i.e., scoring function, hydrous vs unhydrous binding site) are evaluated to identify their closest atomic neighbors in the binding pocket using Discovery Studio working environment.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "Intermolecular atomic neighbors closer than (or equal to) certain predefined distance threshold are assigned an intermolecular contact value of \"one\", otherwise they are assigned a contact value of \"zero\". In the current study two distance thresholds were implemented: 3.5 or 2.5 \u00c5.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "Eventually, this step produces a 2D matrix with row labels corresponding to docked ligands (i.e., according to the particular docking-scoring configuration) and column labels corresponding to different binding site atoms. The matrix is filled with binary code, whereby \"zeros\" correspond to inter-atomic distances above the predefined threshold and \"ones\" for distances below (or equal) the predefined threshold.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "(ii) Each individual column in the matrix is regressed against the corresponding molecular bioactivities (i.e.,-log(IC 50 )). Columns that exhibit negative correlation with bioactivity are inverted, i.e., zeros are converted to ones and vice versa. Emergence of such columns in the final models is generally regarded as pointing to sterically disfavoring groups (excluded volumes).", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "(iii) After excluding inverted columns (negative contacts or exclusion volumes), the resulting binary matrix (which is composed from positively correlated contact columns with bioactivity)", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "is then subjected to genetic algorithm (GA)-based search for optimal contacts columns summation capable of explaining bioactivity variation: In this step GA relies on the evolutionary operations of \"crossover and mutation\" to select optimal combination of columns that have their summation values collinear with bioactivity variation across training compounds (see GA parameters below). The best column-summation model (single model) is", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "selected as representative dbCICA model.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "(iv) GA can be instructed to output best dbCICA models resulting from any predefined number of ligand-receptor intermolecular positive contacts, e.g., best dbCICA models resulting from sets of 4 or 5 or 6 or 7, etc\u2026 concomitant contacts (i.e., summed contact columns). In the current project we instructed GA to scan for the best dbCICA models resulting from 4 contacts and repeat the scan to identify the best summation models for 5, 6, 7, 8, 9 and 10 contacts. Each set of summed contacts is treated independently to identify the corresponding dbCICA model in each case.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "(v) dbCICA algorithm allows variable weights for contacts. This is performed by implementing dual valued genes in the GA, in which every gene encodes for both the corresponding contacts column number and its weight. Column weights are initially randomly distributed in the first generation and subsequently subjected to mutation only (not cross-over) in GA. This option was allowed in the current project to identify intermolecular contacts of higher weights or contributions in the optimal dbCICA models.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "(vi) After identifying optimal summation model(s) based on positive contacts (proportional to bioactivity), dbCICA implements GA to search for optimal summation model resulting from combining inverted columns (negatively proportional to bioactivity, see steps ii and iii) with the optimal positive summation model(s) (generated in step v). The user has the option of choosing any number of negative contacts (excluded volumes or steric clashes) to emerge in the final dbCICA model. In the current experiment we implemented two exclusion settings;", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "either five or ten negative contacts were allowed.", "cite_spans": [], "ref_spans": [], "section": "S12 Docking-Based Comparative Molecular Contacts Analysis (dbCICA)."}, {"text": "The GA toolbox within MATLAB (Version R2007a) was found to be more appropriate in dbCICA modeling. The implemented GA proceeds through the following four basic components: the creation function, cross-over function, mutation function, and fitness function. However, the fitness function in the current dbCICA modeling project was a 5-fold r 2 . In this validation, the training set is divided into two subsets: fit and test subsets. The test subset is randomly selected to represent ca. 20% of the training compounds. This procedure is repeated over 5 cycles; therefore, 5 test subsets with their complementary fit subsets (80% remaining compounds) are selected for each chromosome (i.e., column summation model).", "cite_spans": [], "ref_spans": [], "section": "S13 Genetic Algorithm Implementation in dbCICA Modeling"}, {"text": "The 5 test subsets must cover ca. 100 % of the training compounds by avoiding selecting the same compound in more than one test subset. The fit sets are then utilized to generate 5 sub- ", "cite_spans": [], "ref_spans": [], "section": "S13 Genetic Algorithm Implementation in dbCICA Modeling"}, {"text": "The following steps were utilized to guide development of pharmacophoric models from optimal dbCICA models: (iv) Appearance of certain significant contact atom in the binding site is not necessarily indicative of significant ligand interaction(s) with that particular atom in the binding pocket.", "cite_spans": [], "ref_spans": [], "section": "S14 Building Pharmacophores Corresponding to Successful dbCICA Models."}, {"text": "However, it does indicate significant interaction in the vicinity of that atom.", "cite_spans": [], "ref_spans": [], "section": "S14 Building Pharmacophores Corresponding to Successful dbCICA Models."}, {"text": "(v) Finally, in order to account for the steric constraints of the binding pocket, contact atoms in the binding site that have negative correlations with bioactivity (i.e., those inverted in step (ii) in section S12), were also marked and used as centers for exclusion spheres.", "cite_spans": [], "ref_spans": [], "section": "S14 Building Pharmacophores Corresponding to Successful dbCICA Models."}, {"text": "Exclusion spheres were added manually from DS 2.5 feature library and employing default feature radii (1.2 \u00c5).", "cite_spans": [], "ref_spans": [], "section": "S14 Building Pharmacophores Corresponding to Successful dbCICA Models."}, {"text": "Optimal pharmacophores (both structure-and ligand-based) were validated using receiveroperating characteristic (ROC) curve analysis. ROC analysis assesses the ability of a particular pharmacophore model(s) to correctly classify a group of compounds (decoy testing set) into actives and inactives. The decoy testing set was prepared as described earlier (Alabed et al., 2016) . Briefly, decoy compounds are chosen based on the following one dimentional (1D) properties that allow the evaluation of distance (D) between two molecules (1) ", "cite_spans": [{"start": 353, "end": 374, "text": "(Alabed et al., 2016)", "ref_id": null}], "ref_spans": [], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "Then minimum distances are averaged for all active compounds (D min ). This value is then used as threshold to limit the longest distance between the chosen decoys and corresponding active compounds; otherwise the decoy will be excluded. This method was used to find an average of 36 decoys (presumably inactives)-selected randomly from NCI (National Cancer Institute) -2012 database-for each active compound in the testing set.", "cite_spans": [], "ref_spans": [], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "The testing set (actives and decoys) was screened by successful pharmacophores using \"ligand-pharmacophore mapping\" option of Discovery Studio, while the conformational space of the testing set was generated employing \"Best conformation generation option\" of Discovery Studio.", "cite_spans": [], "ref_spans": [], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "Compounds that are missing one or more feature were discarded from hit list and the mapped hits were scored according to their fit values calculated by Equation (S4) .", "cite_spans": [], "ref_spans": [{"start": 161, "end": 165, "text": "(S4)", "ref_id": null}], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "Thereafter, ROC curve is plotted by considering the highest score of an active molecule as the first threshold then counting the number of decoy compounds within this cut-off value, and both the corresponding sensitivity (Se) and specificity (Sp) are calculated using Equation S9", "cite_spans": [], "ref_spans": [], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "and Equation S10 respectively. This process is repeated using the active molecule possessing the second highest score and so on, until the scores of all active compounds are considered as selection cut-off values. Where AUC value is ranging between (0.5-1) AUC value of 1 is obtained in an optimal ROC curve, while 0.5 value indicates random distributions.", "cite_spans": [], "ref_spans": [], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "2) Overall accuracy (ACC): represents the percentage of molecules that were classified correctly by the screening protocol (Equation S11). This is done by assigning Testing ", "cite_spans": [], "ref_spans": [], "section": "S15 Decoy list and Receiver Operating Characteristic (ROC) Curve Analysis"}, {"text": "Where, N is the total number of compounds in the testing database, A is the number of true active compounds in the testing database.", "cite_spans": [], "ref_spans": [], "section": "Sp N"}, {"text": "3) Overall specificity (SPC): represents the percentage of discarded inactive compounds by a particular virtual screening workflow. Inactive test compounds are assigned a binary score value of one (compound captured) or zero (compound not captured). 4) Overall true positive rate (TPR or overall sensitivity): represents the fraction percentage of captured active compounds from the total number of active compounds. Active test compounds are assigned a binary score value of zero (compound not captured) or one (compound captured).", "cite_spans": [], "ref_spans": [], "section": "Sp N"}, {"text": "Specification Language for specifying substructural patterns in molecules) and Filter by SMARTS when running the Prepare Ligands protocol. This feature allows the user to choose undesired substructures and apply this as a customized filter. Molecules that match any of the selected filters are discarded. Several filters aims at discarding hits containing reactive and alkylating groups have been employed to avoid promiscuous or nonspecific inhibitors. The following reactive moieties have been; the values between brackets indicate the minimum and maximum number of allowed reactive moieties:", "cite_spans": [], "ref_spans": [], "section": "Discovery Studio allows users to Create Features from SMARTS (SMILES Arbitrary Target"}, {"text": "Sulfonyl halide (0-1), Primary alkyl halide (0-1), Epoxide or aziridine (0-1), Sulfonate ester HBA ( The performance of the best representatives of clustered pharmacophore hypotheses generated for HKU4-CoV 3CL pro . Highlighted rows correspond to QSAR-selected pharmacophores in Equation (2) and (3). Table S3 . b Best models from their respective clusters, as judged based on F-statistic, numbers correspond to rank of each hypothesis in each particular run by CATALYST. c The difference between the total cost and the cost of the corresponding null hypotheses. d The correlation coefficients between bioactivity estimates and bioactivities of corresponding training set compounds. e Fischer statistic calculated based on the linear regression between the fit values of collected inhibitors (1-221, Table 1 ) against pharmacophore hypothesis (employing the \"best fit\" option and Equation (S4)) and their respective HKU4-CoV 3CL pro inhibitors bioactivities. Table S5 : Pharmacophoric features and corresponding weights, tolerances and 3D coordinates of Hypo(L-T5-2), Hypo(K-T5-3),and Hypo(N-T1-1) selected by QSAR-guided method.", "cite_spans": [], "ref_spans": [{"start": 301, "end": 309, "text": "Table S3", "ref_id": "TABREF7"}, {"start": 800, "end": 807, "text": "Table 1", "ref_id": null}, {"start": 959, "end": 967, "text": "Table S5", "ref_id": null}], "section": "Discovery Studio allows users to Create Features from SMARTS (SMILES Arbitrary Target"}, {"text": "Chemical Features (Table S2 under Supporting Material), HYPOGEN run number 5 (Table S3 under Supporting Material).The pharmacophore model includes 5 exclusion volumes of 1.2 \u00c5 tolerance spheres and at the following (X, Y, Z) coordinates: (3.594, -1.454, -2.361), (2.304, -4.435, -1.596), (6.563, 4.45, 5.873), (-2.555,-1.838, 5.679), and (-3.96, 3.752, -0.844). Hypo (N-T1-1) b : corresponds to the pharmacophore model generated by subset N (Table S2 under Supporting Material), HYPOGEN run number 1 (Table S3 under Supporting Material). Hypo (L-T5-2) C : corresponds to the pharmacophore model generated by subset L (Table S2 under Supporting Material), HYPOGEN run number 5 (Table S3 under Supporting Material).The pharmacophore model includes one exclusion volumes of 1.2 \u00c5 tolerance spheres and at the following (X, Y, Z) coordinates: (-1.183, -2.212, and4.195) . 3.2 \u00b1 0 -0.2 \u00b1 2 105360 -3.8 \u00b1 1 -2.8 \u00b1 3 105691 -1.8 \u00b1 0 5.6 \u00b1 13 120176 -0.2 \u00b1 2 4.3 \u00b1 7 120178", "cite_spans": [{"start": 839, "end": 865, "text": "(-1.183, -2.212, and4.195)", "ref_id": null}], "ref_spans": [{"start": 18, "end": 27, "text": "(Table S2", "ref_id": "TABREF6"}, {"start": 77, "end": 86, "text": "(Table S3", "ref_id": "TABREF7"}, {"start": 441, "end": 450, "text": "(Table S2", "ref_id": "TABREF6"}, {"start": 500, "end": 509, "text": "(Table S3", "ref_id": "TABREF7"}, {"start": 617, "end": 626, "text": "(Table S2", "ref_id": "TABREF6"}, {"start": 676, "end": 685, "text": "(Table S3", "ref_id": "TABREF7"}], "section": "Definitions"}, {"text": "17.6 \u00b1 9 51.9 \u00b1 7 120181 0 \u00b1 1 3.1 \u00b1 6 128947", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "14.5 \u00b1 1 28 \u00b1 7 128949 7.1 \u00b1 2 15.4 \u00b1 8 129490 -1.7 \u00b1 0 -2.6 \u00b1 4 129492 -1.1 \u00b1 1 -0.8 \u00b1 4 132526 8.5 \u00b1 2 -5.3 \u00b1 4 139984 -0.7 \u00b1 1 0.3 \u00b1 6 141051 -2.8 \u00b1 1 -4.1 \u00b1 8 176396 2.6 \u00b1 1 1.2 \u00b1 4 176398", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "3.1 \u00b1 2 0.6 \u00b1 4 202876 4.9 \u00b1 1 2.3 \u00b1 3 205585 -1.7 \u00b1 0 -10.5 \u00b1 7 273940", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "2.3 \u00b1 0 1.6 \u00b1 5 306859", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "1.3 \u00b1 1 -1.5 \u00b1 5 334026", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "2.4 \u00b1 1 -0.4 \u00b1 4 343728 0.5 \u00b1 1 -8.8 \u00b1 6 350115", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "3.4 \u00b1 1 -0.3 \u00b1 3 350118", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "5.4 \u00b1 1 3.5 \u00b1 7 382729", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "3.1 \u00b1 1 2.3 \u00b1 4 622218 2.2 \u00b1 1 1.3 \u00b1 4 624438 0 \u00b1 1 -1.7 \u00b1 5 640976 -5.2 \u00b1 2 -27.8 \u00b1 2 640982 -8.9 \u00b1 2 -19.2 \u00b1 2 644748 -11.3 \u00b1 2 -17.8 \u00b1 2 644753 -0.9 \u00b1 2 -23.3 \u00b1 1 644775", "cite_spans": [], "ref_spans": [], "section": "Definitions"}, {"text": "4.5 \u00b1 1 -2 \u00b1 1 667914 -2.6 \u00b1 2 -14 \u00b1 3 667917 -8.1 \u00b1 2 -13.9 \u00b1 4 671173 -4.4 \u00b1 2 -13.2 \u00b1 4 674065 -8.1 \u00b1 1 -17.1 \u00b1 4 683637 -13.3 \u00b1 1 -22.3 \u00b1 4 685876 -6 \u00b1 0 -9.3 \u00b1 4 726558 -4.5 \u00b1 4 -5.6 \u00b1 3 Figure S1 : The chemical structures and NCI codes of the identified hits using QSAR-guided and dbCICA derived pharmacophores. Figure S4 : The dose-response curves of compounds (A) 222, (B) 223 against MERS-CoV 3CL pro . See Section 2.6 for details. The IC 50 values were determined at ambient temperature from 100 \u03bcL assays performed in triplicate in the following buffer: 50 mM HEPES, 0.1 mg/mL BSA, 0.01% TritonX-100, 2 mM DTT. Each inhibitor was tested at concentrations ranging from 2.5-400 \u03bcM (10-400 \u03bcM for compound 223). 1 \u03bcL of 100X inhibitor stock in DMSO was added to 79 \u03bcL of enzyme in assay buffer and the enzyme-inhibitor mixture was incubated for 5 min. The reaction was initiated by the addition of 20 \u03bcL of 10 \u03bcM UIVT3 substrate, producing final concentrations of 500 nM MERS-CoV 3CL pro and 2 \u03bcM UIVT3 substrate. The SigmaPlot Enzyme Kinetics Wizard was used to fit the percent inhibition data and associated standard error to either the Hill equation. The shape of (A), where a linear inhibition of fluorescence up to a maximum inhibition, indicates the influence of the Inner Filter Effect. Error expressed as 95% Confidence Intervals. Error bars represent the standard error for triplicate data. The error bars are within the symbols.", "cite_spans": [], "ref_spans": [{"start": 192, "end": 201, "text": "Figure S1", "ref_id": null}, {"start": 318, "end": 327, "text": "Figure S4", "ref_id": null}], "section": "Definitions"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Hypo (SB-2) b : The pharmacophore model includes 5 exclusion volumes of 1.2 \u00c5 tolerance spheres and at the following (X,Y,Z) coordinates: (-8.00, -26.98, 21.00), (-14.04, -22.99, 26.53), (-9.64,-25.17, 23.88), (-3.91, -17.33, 29.19), (-0.23, -19.26, 29.21)", "authors": [{"first": "", "middle": [], "last": "Hypo", "suffix": ""}], "year": null, "venue": "38,25.93), (-11.79,-26.18,25.47), (-7.21,-18.97,25.65)", "volume": "22", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "HIPHOP-REFINE utilizes inactive training compounds to create exclusion volumes that resemble the steric constrains of the binding pocket. It identifies spaces occupied by the conformations of inactive compounds and free from conformations of active ones. These areas are then filled with exclusion volumes. The user defines how many molecules map the selected pharmacophore hypothesis partially or completely via the Principal and Maximum Omitted Features (MaxOmitFeat) parameters. Active compounds are assigned MaxOmitFeat parameter of zero and Principal value of 2 to direct the software to fit all their chemical moieties against all the pharmacophoric features of the particular binding hypothesis. However, inactive compounds are allowed to miss one or more features by assigning them a MaxOmitFeat of 1 or 2, and Principal value of zero. Moderately active compounds are normally assigned a principal value of 1 and a MaxOmitFeat of 0 or 1 to encode their intermediate status. On the other hand, compounds that are inactive due to steric clashes within the binding pocket were assigned MaxOmitFeat value of zero. This value instructs HipHop to force inactive compound(s) to fit all the pharmacophoric features of the binding model, and therefore permits the software to identify spaces occupied by excess structural fragments of such inactive compounds and fill them with exclusion volumes.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "(v) Poses which result in protein clashes are removed. (vi) a final BFGS pose optimization stage is performed using a simple pair-wise score (similar to Piecewise Linear Potential). The top scoring ligand poses are retained (vii) hydrogen atoms are added back to the docked ligands .(viii) optionally, CHARMm minimization can be carried out to reduce steric clashes caused by added hydrogen atoms. The following LibDock parameters were implemented in the presented project: (i) Prior to docking, the Discovery Studio module CAT-CONFIRM was used to generate a maximum of 250 conformers (not exceeding an energy threshold of 20 kcal/mol from the most stable conformer) for each ligand employing CAESAR conformation generation option. (ii) a binding site sphere of 9.7 \u00c5 radius surrounding the centre of the co-crystallized ligand (4F4) was added. (iii) the maximum number of binding site hotspots was set to 100. (iv) ligand-tohotspots matching RMSD tolerance value was set to 0.25 \u00c5. (v) The maximum number of poses saved for each ligand during hotspots matching before final pose minimization = 100. (vi) Maximum number of poses to be saved for each ligand in the binding pocket = 100. (vii) Minimum LibDock score (poses below this score are not reported) = 100. (viii) Maximum number of rigid body minimization steps during the final pose optimization (using BFGS method) = 50. (ix) Maximum number of steric clashes allowed before the pose-hotspot alignment is terminated (specified as a fraction of the heavy atom count) = 0.1. (x) Maximum value for nonpolar solvent accessible surface area for a particular pose to be reported as successful = 15.0 \u00c5 2 . (xi) Maximum value for polar solvent accessible solvent area for a particular pose to be reported as successful = 5.0 \u00c5 2 . (xii) No final ligand minimization was implemented (i.e., in the binding pocket).", "latex": null, "type": "figure"}, "FIGREF2": {"text": "(i) A set of ligand conformations are generated using high-temperature molecular dynamics starting with different random seeds. (ii) Random orientations of the conformations are produced by translating the center of the ligand to a specified location within the receptor active site, and performing a series of random rotations. (iii) A softened energy is calculated and the orientation is kept if the energy is less than a specified threshold. This process continues until either the desired number of low-energy orientations is found, or the maximum number of bad orientations has been tried. (iv) Each orientation is subjected to simulated annealing molecular dynamics. The temperature is heated up to a high preset temperature then cooled to the target temperature. (v) A final minimization of the ligand in the rigid receptor using non-softened potential is performed. For each final pose, the CHARMm energy (interaction energy plus ligand strain) and the interaction energy alone are calculated. The poses are sorted by CHARMm energy and the top scoring (most negative, thus favorable to binding) poses are retained.", "latex": null, "type": "figure"}, "FIGREF3": {"text": "models employing the same chromosome. Sub-models resulted are utilized to predict the bioactivities of the corresponding testing subsets. Lastly, the predicted values of all 5 test subsets are correlated with their experimental counterparts to determine the corresponding 5fold r 2 . The subsequent parameters were chosen for GA genetic manipulation: (i) Size of chromosome population = 200, (ii) Rate of mating (crossover fraction): 80% (iii) Elite count = 1 (iv) Maximum number of generations which is needed to exit from GA iteration cycles and completion of the algorithm = 1000. Based on these parameters, the numbers of each type of children in the offspring generation is as follows: There is 1 elite child (correspond to the individual in the parents' generation with the best fitness value), and there are 199 individual children other than the elite child. The algorithm rounds 0.8 (crossover fraction) x 199 = 159.2 to 159 to get the number of crossover children and the remaining 40 mutation population. The elite child is passed to the offspring population without changes.", "latex": null, "type": "figure"}, "FIGREF4": {"text": "configurations that yielded the best dbCICA models were chosen. The corresponding docked poses/conformers of the most potent ligands (IC 50 < 5.0 \u00b5M) were retained in the binding pocket while other less potent ligands were discarded. (ii) Afterward, the particular optimal dbCICA model was used to predict the bioactivity of potent compounds, i.e., by substituting the number of contacts of each docked compound in the regression equation corresponding to the dbCICA model. Well-behaved potent compounds were kept in the binding pocket for subsequent manipulation. Well-behaved compounds are defined as those training compounds that have their bioactivities well-predicted by the selected optimal dbCICA model, i.e., they have the least residual difference between fitted and experimental bioactivities as predicted by dbCICA model. (iii) Significant positive molecular contacts in binding site, i.e., those that have weights of 2 or 3, were marked and carefully evaluated to identify their closest ligands moieties. Agreement and consensus among potent, well-behaved training compounds to place moieties of common physicochemical properties adjacent to significant contact atom (as defined by the dbCICA model) permit placing a corresponding pharmacophoric feature onto that region. For example, if potent, well-behaved docked compounds agreed on placing aromatic rings adjacent to certain dbCICA significant contact point (within the predefined distance threshold) then a hydrophobic aromatic feature is placed on top of the aromatic rings. The Pharmacophoric query features were added manually from Discovery Studio feature library and employing default feature radii (1.6 \u00c5 or 2.2 \u00c5).", "latex": null, "type": "figure"}, "FIGREF5": {"text": "The number of hydrogen bond donors (NumHBD), (2) The number of hydrogen bond acceptors (NumHBA), (3) The number of non-polar atoms (NP) is the summation of Br, Cl, F, I, S and C atoms in a particular molecule. Active compounds were defined as those possessing anti-HKU4-CoV 3CL pro inhibitory IC 50 < 36 \u00b5M. The distances between active compounds in the decoy testing set were calculated using Euclidean Distance (Equation S8)", "latex": null, "type": "figure"}, "FIGREF6": {"text": "TP (true positive) is the number of active compounds that are captured by the pharmacophore under concern, FN (false negative) is the number of active compounds discarded from the hits list, TN (true negative) is the number of discarded decoys , while FP (false positive) is the number of captured decoys .The ROC curve is an ideal distribution curve, i.e., there is no overlapping between the scores of active molecules and the scores of the decoys, the ideal ROC curve, which corresponds to Se = 1 and Sp = 1, continues as a horizontal straight line to the upper-right corner where all active compounds are captured and all decoy compounds are retrieved. The success of a certain virtual screening workflow can be judged according to the following criteria: 1) Area under the ROC curve (AUC):", "latex": null, "type": "figure"}, "FIGREF7": {"text": "-1), Phosphonate ester (0-1), Long aliphatic chain (0-1), Peroxide (0-1), 1-2 Dicarbonyl (", "latex": null, "type": "figure"}, "FIGREF12": {"text": "Bond Acceptor, HBD: Hydrogen Bond Donor, RingArom: Ring Aromatic, Hbic: Hydrophobic, EV: maximum number of allowed exclusion spheres. Numbers in brackets refer to the allowed ranges of corresponding features in each pharmacophore modeling run. c Max-Min refers to the allowed range of pharmacophoric features in each model. d Spacing refers to the maximum interfeature distance in picometers. Other parameters were set to their default values. e These runs failed to generate any pharmacophore models.", "latex": null, "type": "figure"}, "FIGREF13": {"text": "NMR and MS analysis of compound 222. NMR and MS analysis of compound 223.", "latex": null, "type": "figure"}, "TABREF0": {"text": "value of 2. The deviation between the experimentally determined activities of the training set and their estimated values adds to the error cost. The activity of any compound can be Where, I = the intercept of the regression line gained by plotting the log of the biological activity of the training set compounds against the Fit values of the training compounds. The Fit value for any compound is calculated automatically employing Equation (S4). Fit = mapped hypothesis features \u00d7 W [1\u2212 \u03a3(disp/tol) 2 ]\u2026\u2026..\u2026. (S4)", "latex": null, "type": "table"}, "TABREF1": {"text": "\uf0b7 Mating operation: two parent chromosomes are combined to generate new solutions (offspring). Mutation operator: a mutation operator changes one or more bits in the chromosome to its complement.\uf0b7 Maximum number of generations to exit and complete the algorithm. The independent descriptors were generated as follows: The chemical structures of the inhibitors were imported into Discovery Studio as standard 3D single conformer representations in SD format.", "latex": null, "type": "table"}, "TABREF2": {"text": "compounds a binary score value of one (compound captured) or zero (compound not captured).", "latex": null, "type": "table"}, "TABREF3": {"text": "The structures of HKU4-CoV 3CL pro inhibitors utilized in modeling.", "latex": null, "type": "table"}, "TABREF4": {"text": "The structures of HKU4-CoV 3CL pro inhibitors utilized in modeling.", "latex": null, "type": "table"}, "TABREF5": {"text": "The structures of HKU4-CoV 3CL pro inhibitors utilized in modeling.", "latex": null, "type": "table"}, "TABREF6": {"text": "Training subsets (extracted from Table S1) employed in exploring the pharmacophoric space of HKU4-CoV 3CL pro inhibitors.", "latex": null, "type": "table"}, "TABREF7": {"text": "Training subsets and HYPOGEN run parameters employed for exploring HKU4-CoV 3CL pro pharmacophoric space.", "latex": null, "type": "table"}, "TABREF8": {"text": "Training subsets and HYPOGEN run parameters employed for exploring HKU4-CoV 3CL pro pharmacophoric space.", "latex": null, "type": "table"}, "TABREF9": {"text": "Training subsets and HYPOGEN run parameters employed for exploring HKU4-CoV 3CL pro pharmacophoric space.", "latex": null, "type": "table"}, "TABREF10": {"text": "Training subsets and HYPOGEN run parameters employed for exploring HKU4-CoV 3CL pro pharmacophoric space.", "latex": null, "type": "table"}, "TABREF11": {"text": "", "latex": null, "type": "table"}, "TABREF13": {"text": "Z -1.078 -2.679 -1.468 -2.089 1.064 1.116 Hypo (K-T5-3) a : corresponds to the pharmacophore model generated by subset K", "latex": null, "type": "table"}, "TABREF14": {"text": "Training subset used for adding excluded spheres for Hypo(K-T5-3/N-T1-1) using HIPHOP-REFINE module of CATALYST.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>a Compound\n</td><td>IC50(\u00b5M) </td><td>Principal </td><td>b MaxOmitFeat\n</td></tr><tr><td>1 </td><td>0.33 </td><td>2 </td><td>0 </td></tr><tr><td>2 </td><td>0.41 </td><td>2 </td><td>0 </td></tr><tr><td>3 </td><td>1.2 </td><td>2 </td><td>0 </td></tr><tr><td>4 </td><td>1.2 </td><td>2 </td><td>0 </td></tr><tr><td>27 </td><td>1.5 </td><td>2 </td><td>0 </td></tr><tr><td>6 </td><td>1.6 </td><td>2 </td><td>0 </td></tr><tr><td>8 </td><td>1.9 </td><td>2 </td><td>0 </td></tr><tr><td>10 </td><td>2.2 </td><td>2 </td><td>0 </td></tr><tr><td>31 </td><td>2.7 </td><td>2 </td><td>0 </td></tr><tr><td>12 </td><td>2.8 </td><td>2 </td><td>0 </td></tr><tr><td>13 </td><td>3.1 </td><td>2 </td><td>0 </td></tr><tr><td>32 </td><td>3.4 </td><td>2 </td><td>0 </td></tr><tr><td>34 </td><td>4.2 </td><td>2 </td><td>0 </td></tr><tr><td>36 </td><td>7 </td><td>2 </td><td>0 </td></tr><tr><td>18 </td><td>8.8 </td><td>2 </td><td>0 </td></tr><tr><td>19 </td><td>16 </td><td>1 </td><td>0 </td></tr><tr><td>18 </td><td>17.2 </td><td>1 </td><td>0 </td></tr><tr><td>42 </td><td>18.3 </td><td>1 </td><td>0 </td></tr><tr><td>46 </td><td>52.3 </td><td>1 </td><td>0 </td></tr><tr><td>51 </td><td>147 </td><td>1 </td><td>0 </td></tr><tr><td>48 </td><td>192.3 </td><td>1 </td><td>0 </td></tr><tr><td>23 </td><td>200 </td><td>1 </td><td>0 </td></tr><tr><td>50 </td><td>238 </td><td>1 </td><td>0 </td></tr><tr><td>49 </td><td>250 </td><td>1 </td><td>0 </td></tr><tr><td>128 </td><td>263.2 </td><td>1 </td><td>0 </td></tr><tr><td>137 </td><td>277.7 </td><td>1 </td><td>0 </td></tr><tr><td>52 </td><td>277.7 </td><td>1 </td><td>0 </td></tr><tr><td>146 </td><td>294 </td><td>1 </td><td>0 </td></tr><tr><td>165 </td><td>312.5 </td><td>1 </td><td>0 </td></tr><tr><td>25 </td><td>333.3 </td><td>1 </td><td>0 </td></tr><tr><td>182 </td><td>357 </td><td>0 </td><td>0 </td></tr><tr><td>187 </td><td>357 </td><td>0 </td><td>0 </td></tr><tr><td>219 </td><td>625 </td><td>0 </td><td>0 </td></tr><tr><td>221 </td><td>833.3 </td><td>0 </td><td>2 </td></tr></table></body></html>"}, "TABREF15": {"text": "HKU4-CoV 3CL pro based pharmacophore models selected by best dbCICA models.", "latex": null, "type": "table"}, "TABREF16": {"text": "The results of in vitro screening of the in silico hits captured by QSARguided pharmacophores.", "latex": null, "type": "table"}, "TABREF17": {"text": "The results of in vitro screening of the in silico hits captured by dbCICAderived pharmacophores.", "latex": null, "type": "table"}}, "back_matter": []}